EPISODE · Apr 20, 2015 · 6 MIN
Deciphering the Heterogeneity Within EGFR-mutant Lung Cancer
from Journal of Clinical Oncology (JCO) Podcast · host Geoffrey R. Oxnard
A meta-analysis of 7 randomized trials comparing EGFR kinase inhibitors to chemotherapy for advanced EGFR-mutant lung cancer has shown that some populations gain greater benefit from targeted therapy – namely never-smokers, woman, and tumor harboring exon 19 deletions.
NOW PLAYING
Deciphering the Heterogeneity Within EGFR-mutant Lung Cancer
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m